# A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct06692166/  
OnCo record `nct06692166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 9MW2821 in cervical cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06692166 by Mabwell (Shanghai) Bioscience Co., Ltd., with 420 participants planned, started 2024-09-10 and due to reach its primary completion in 2027-12-09. Interventions recorded: 9MW2821 and Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06692166
- Phase: 3
- Setting: A Randomized, Open-label, Phase 3 Study to Evaluate 9MW2821 vs Treatment of Physician's Choice in Subjects With Recurrent or Metastatic Cervical Cancer Who Progressed on or After Platinum-based Chemotherapy
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT06692166: https://clinicaltrials.gov/study/NCT06692166

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)

---
JSON: https://onco.cc/api/v1/entities/nct06692166.json